posted
VEGF Has over $1.50 cash per share per yahoo
Has positive revenues per share per yahoo
The huge sell-off was due to the Genasis trial that was voluntary stopped due to 3 issues with test subjects. The issues were treated and VEGF as well as BSX are evaluating the data to determine what to do with the project, and whether to continue with the trials. It is quite likely that the trials will recommence.
VEGF has multiple other drugs in their development pipeline with ongoing trials in effect.
Is a great time to buy up some cheap shares for a short to mid term hold play.
IP: Logged |
UBBFriend: Email this page to someone!
Printer-friendly view of this topic
